Kyverna Therapeutics Analyst Ratings
Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Hold Rating, Cuts Target Price to $6
Kyverna Therapeutics Is Maintained at Overweight by Wells Fargo
Wells Fargo Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Cuts Target Price to $24
Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40
Analysts Offer Insights on NA Companies: Kyverna Therapeutics, Inc. (KYTX), Mural Oncology Plc (MURA) and Copa Holdings (CPA)
UBS Initiates Kyverna Therapeutics(KYTX.US) With Buy Rating, Announces Target Price $13
Kyverna Therapeutics Initiated With a Buy at UBS
Rodman & Renshaw Initiates Kyverna Therapeutics(KYTX.US) With Buy Rating, Announces Target Price $16
Kyverna Therapeutics Initiated With a Buy at Rodman & Renshaw
Kyverna Therapeutics Analyst Ratings
Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Hold Rating, Maintains Target Price $7
Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40
J.P. Morgan Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $33
Kyverna Therapeutics Analyst Ratings
Analysts Offer Insights on NA Companies: Kyverna Therapeutics, Inc. (KYTX), Smith Douglas Homes Corp. Class A (SDHC) and Kayne Anderson BDC, Inc. (KBDC)
H.C. Wainwright Initiates Kyverna Therapeutics(KYTX.US) With Hold Rating, Announces Target Price $7
Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40